Lightnews — Scholar-powered news

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 5d

The EARLY study will track patients with incidental, asymptomatic IBD to uncover genetic, immune & clinical markers of disease in its preclinical phase. With 10-year follow-up, it aims to predict outcomes & guide early intervention strategies.

journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 5d

Survey of Moroccan gastroenterologists shows heavy workloads (50h+/week) linked to high rates of musculoskeletal (87%), digestive (71%), anxiety (24%), depression (46%), and burnout (72%). Younger doctors most affected, with worse work–life balance.

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 5d

US cohort shows vitamin D deficiency increases risk of cirrhosis HR 1.30, HCC HR 1.22, and mortality HR 1.14. Achieving sufficiency lowered death risk HR 0.93 but not cirrhosis. Lowest liver risk seen at 40–60 ng/mL, suggesting a U-shaped pattern.

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 5d

Review outlines strategies for 10–20 mm non-pedunculated colorectal polyps: CSP offers low AE risk, modified EMR boosts en bloc rates by 15–20%, while ESD is preferred for invasive/fibrotic cases. Emerging bipolar/low-power snares may cut thermal AEs.

journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 12d

Study (n=50) in unresectable #HCC: response to TACE was tied to peripheral T-cell profiles. Non-responders had more senescent/exhausted CD8+ T cells & fewer memory stem cells. Baseline CD8+ TSCM & TSenescence subsets may predict TACE efficacy & survival.

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 12d

Cross-sectional study (n=345) in China: 39.7% of ulcerative colitis pts reported disability (IBD-DI). Disability linked to higher disease activity, fatigue, depression & lower BMI. Independent risk factors: BMI, Mayo score, fatigue, depression.

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 12d

Retrospective study (n=65) of HER2+ advanced #GastricCancer treated with trastuzumab deruxtecan: ORR 36%, median OS 7.7 mo. Early tumor shrinkage was a strong predictor of longer PFS (HR 0.21) & OS (HR 0.23). T-DXd showed efficacy with manageable safety.

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 12d

Retrospective cohort in Vietnam: delayed ERCP for stone-induced acute cholangitis gave comparable outcomes to early ERCP, with similar mortality/readmission. Early ERCP shortened hospital stay, but dERCP offers a safe option in resource-limited settings

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 12d

Prospective study in #IBD: 91.8% accepted switch from originator adalimumab to biosimilars. Persistence 60.4% at 12 mo; remission maintained in 90.4%. Injection site pain was main discontinuation cause. Majority reported positive experience with switch

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 20d

Retrospective analysis of 1259 colorectal polyps (1025 pts) after EMR shows complete titanium clip closure reduces delayed postpolypectomy bleeding (#DPPB). Partial closure, male sex & larger polyps were significant risk factors. Complete closure is key

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 20d

Multicentre Korean cohort (n=127) assessed switching #IBD pts from IV to SC infliximab. 1-yr treatment persistence was high (92.1%) with no difference between remission & non-remission groups. SC IFX showed stable or improved outcomes & manageable safety

journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · 20d

Review on #GIcancer immunotherapy highlights integrated biomarker strategies—from molecular (MSI, TMB, PD-L1), histopathology (CD8+/Treg ratio), to imaging. Combining genetic & imaging data may improve patient selection & treatment monitoring

Read here: journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · May 16

In a 240-patient cohort, fecal microbiota transplant for recurrent C. difficile infection failed in 24.6% of cases (18.3% recurrence, 7.1% death within 1 year). Older age, multiple prior episodes, and diabetes were significantly associated with failure.

journals.sagepub.com/doi/epdf/10....

1

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · May 16

In the phase IIIb CDI-SCOPE trial, fecal microbiota, live-jslm (REBYOTA®) delivered via colonoscopy prevented CDI recurrence in 95.1% of patients over 8 weeks.
Only 9.8% experienced mild, RBL-related TEAEs.
Safe, practical, and effective.

🔗 journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · May 16

🩸 A 29-expert Delphi panel reached consensus on 36 statements for managing delayed post-polypectomy bleeding.

Key recommendations: risk stratification to reduce unnecessary colonoscopies, and guidance for antithrombotic and hemostatic management

🔗 journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · May 16

🧠 In 1344 non-sedated EGD patients, a pre-procedural anxiety score >36 predicted higher odds of incomplete or poor-quality exams (AUC=0.720).
Each 1-point increase in STAI-I raised failure odds by 3.8%.
Routine anxiety screening could improve outcomes

🔗 journals.sagepub.com/doi/epdf/10....

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · May 9

In unresectable perihilar cholangiocarcinoma, endoscopic therapy goes beyond biliary drainage.
ERCP-based approaches + adjuncts like RFA, PDT & EUS methods offer therapeutic promise where surgery isn’t an option.

doi.org/10.1177/1756...

1 1

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · May 9

Smoking, MASLD, cerebrovascular disease, H. pylori persistence, multiple lesions & severe atrophic gastritis all linked to metachronous gastric cancer post-curative ESD.
A nomogram showed strong predictive accuracy (C-index up to 0.845).

doi.org/10.1177/1756...

1

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · May 9

Anti-reflux mucosectomy significantly improved LES pressure, Hill’s grade, and GERD-related symptom scores vs argon plasma coagulation in Barrett’s esophagus.
A stronger reflux barrier with lower lesion residue—supporting ARMS as a dual-target strategy.

doi.org/10.1177/1756...

1 1

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · May 9

In MASLD and MetALD, current smoking significantly worsened survival and increased risks of cirrhosis, CVD, and liver-related mortality. Never smokers had lowest risks across most outcomes.
📊 Supports strong cessation strategies in liver disease care.

doi.org/10.1177/1756...

Reposted by Therapeutic Advances in Gastroenterology

Jen L, PhD @drjkyl.bsky.social · May 2

Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings - Apr 24, 2025
@journals.sagepub.com @tagastroenterol.bsky.social
journals.sagepub.com/doi/10.1177/...
#oncsky #openaccess

2 4

Reposted by Therapeutic Advances in Gastroenterology

Jen L, PhD @drjkyl.bsky.social · May 2

Factors associated with failure of fecal microbiota transplant for recurrent Clostridioides difficile infection - Apr 23, 2025
@journals.sagepub.com @tagastroenterol.bsky.social

journals.sagepub.com/doi/10.1177/...

#gastroenterology #medicine #medsky #openaccess

1 2 3

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · Apr 16

🧠 LLMs show promise for GI research—supporting clinical decisions, data extraction & patient comms—but risks like hallucinations & bias remain.
This framework outlines practical steps: goal-setting, fine-tuning, EHR integration & real-world validation

🔗 journals.sagepub.com/doi/epdf/10....

1 1

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · Apr 16

Thanks to Robert Dorrell, Alexa Cecil, Swati Pawa, Gregory Russell and Rishi Pawa for this data-driven call for individualized LAMS removal timing in endoscopic necrosectomy

1

Therapeutic Advances in Gastroenterology @tagastroenterol.bsky.social · Apr 16

🧠 In 104 patients with walled-off necrosis, tailoring LAMS dwell time by imaging & symptoms led to similar success & safety—despite longer stent time (>4wks) in necrosis-heavy cases. Early removal = fewer necrosectomies.

Read more: journals.sagepub.com/doi/epdf/10....

1 1 2